2022
Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles
Goutman S, Boss J, Iyer G, Habra H, Savelieff M, Karnovsky A, Mukherjee B, Feldman E. Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles. Muscle & Nerve 2022, 67: 208-216. PMID: 36321729, PMCID: PMC9957813, DOI: 10.1002/mus.27744.Peer-Reviewed Original ResearchConceptsBody mass indexBody mass index trajectoriesMetabolomic profilesAmyotrophic lateral sclerosis survivalAmyotrophic lateral sclerosisAmyotrophic lateral sclerosis participantsMass indexBody mass index lossBody mass index trajectory groupsSelf-reported body heightParticipants lost weightShorter survivalProspective cohortSurvival associationsStudy entryMetabolomic networksGeneralized estimating equationsSymptom onsetBMI trendsWeight lossSurvivalBile acidsBody heightTrajectory groupsPotential mechanisms
2016
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop G, Zhong J, Peters M, Goud A, Chen Y, Davis S, Mukherjee B, Rajagopalan S. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. Journal Of Diabetes And Its Complications 2016, 32: 113-122. PMID: 29074120, DOI: 10.1016/j.jdiacomp.2016.08.018.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsOral anti-diabetic agentsGLP-1RABackground therapyGlycemic efficacyWeight lossGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsActive comparator armLong-acting GLP-1RAType 2 diabetes mellitusPeptidase-4 inhibitorsTreatment of type 2 diabetes mellitusIncretin-based therapiesActive comparator drugShort-acting agentsWeight loss effectsClinical trial evidenceType 2 diabetesRandomized controlled trialsReceptor agonistsAnti-diabetic agentsIncretin therapiesComparator armComparator therapy